This finding could be further explored and if more evidence emerges, Bcl-2 could be a potential new therapeutic target in G3 NEC, although anti-Bcl-2 therapies have not been successfully developed so far [25]. This evidence concerns the gene BCL2 and neuroendocrine carcinoma.